Delivery Order SPE2DB25D3005-SPE2DB25FQJTS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,049.31 to AmerisourceBergen Drug Corp for RYTARY ER 36.25 mg-145 mg capsules (100-count), a Parkinson's disease medication. This firm fixed price delivery order, issued on September 16, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was competitively made with no...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,013.49 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 36.25 MG-145 MG capsules (100-count) under a firm fixed-price contract. The award was made on September 15, 2025, with an ultimate completion date of September 16, 2025, and does not include a set-aside designation. Performance will be executed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a $11,176.77 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of RYTARY ER 23.75 MG-95 MG, a pharmaceutical product used in the treatment of Parkinson's disease. The contract was awarded on July 24, 2025, with an ultimate completion date of July 25, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $1,906.55 to AmerisourceBergen Drug Corp for RYTARY ER 36.25 mg-145 mg capsules (100-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of April 24, 2025, and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA. The product will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,935.59 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 48.75 MG-195 MG capsules (100-count units). This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 6, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $6,559.33 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of RYTARY ER 36.25 mg–145 mg capsules (100-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $13,679.70 to AmerisourceBergen Drug Corp for the supply of Rytary ER 36.25 mg-145 mg capsules (100 count) under a firm fixed price contract. This competitive award, issued on August 26, 2025, with an ultimate completion date of August 27, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,483.62 to AmerisourceBergen Drug Corp for RYTARY ER 23.75 mg-95 mg capsules (100-count units) on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitively awarded transaction. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency awarded a delivery order valued at $1,670.46 to AmerisourceBergen Drug Corp for RYTARY ER 48.75 mg-195 mg capsules (100-count supply) on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed-price delivery order with no set-aside designation, to be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,989.57 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 48.75 MG-195 MG capsules (100-count packages). This firm fixed-price delivery order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive award under DLA's existing supply chain framework. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- SPE2DB25D3005Indefinite Delivery Contract
- SPE2DB25D3005-SPE2DB25FQJTSDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,910.55 to AmerisourceBergen Drug Corp for RYTARY ER 48.75 mg-195 mg capsules (100-count), a Parkinson's disease medication. This firm fixed-price delivery order, issued on September 16, 2025, with an ultimate completion date of September 17, 2025, was awarded competitively without a set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under the company's broader pharmaceutical supply relationship with the federal government. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. As a primary pharmaceutical vendor for the Defense Health Agency and military healthcare systems, AmerisourceBergen supplies a comprehensive range of medications and medical supplies supporting federal healthcare requirements globally. The company's federal portfolio demonstrates extensive capability in delivering specialty and brand-name pharmaceuticals across multiple therapeutic domains to support military and veteran healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 9/16/25 |